Background. Pseudomonas aeruginosa isolates from sputum cultures do not always require treatment, often representing chronic airways colonization. By releasing sputum P. aeruginosa antimicrobial susceptibility results, only after specific phone request by treating doctors, we aimed to reduce the use of ciprofloxacin without compromising clinical outcomes.
Rates of ciprofloxacin resistance were lower postintervention [2.8% (3/108) vs. 16.7% (18/108); P = 0.0006], reaffirmed by SQL database search of the OMNI-Client [9.30% (32/343) vs. 15.00% (60/399); P = 0.0187].
Ciprofloxacin usage against resistance over time
There was no difference in length of stay, 30-day readmission, and mortality.
Conclusion. This study offers a successful model of collaboration between the microbiology laboratory and antimicrobial stewardship activity. It showed a reduction in the use of ciprofloxacin with possible influence on P. aeruginosa resistance rates, without affecting patient outcomes.
Disclosures. (Figure 1) . In community-acquired pneumonia (CAP) interventions to change prescribing from FQs to a β-lactam (BL) + atypical agent (combo) would result in a doubling of days of therapy (DOTs) for that indication. However, combo regimens may provide patient safety and abx resistance benefits that are not captured by the DOT metric. This study examines the relationship between utilization of FQ-sparing, combo therapy for patients with CAP and associated impact on AS metrics.
Methods. This was a retrospective, multicenter study of abx utilization for treatment of CAP before and after an FQ-sparing initiative. DRG codes identified abx use specific to CAP. Abx use was measured using medication administration reports to calculate DOT per 1,000 patient-days.
Results. The FQ initiative yielded a 40.4% reduction in overall FQ use (P < 0.001), though overall abx consumption did not change (Table 1, Figure 2) . A decrease in FQ use in CAP was observed (−42%, P < 0.001), while combo use increased (+43%, P < 0.001).
Conclusion. A system-wide FQ-sparing initiative resulted in significant increases in use of combo abx for CAP. Although considered an appropriate intervention for patient safety and resistance reasons, unintended impacts on standard consumption metrics should be considered when comparing use within or across institutions. The use of alternative metrics, such as point-prevalence surveys, may be indicated. Examination of impact on overall DOT in additional disease states and at the facility-specific level is needed. 
